The CEO of opioid drug maker AmerisourceBergen got a $14 million raise thanks to a controversial accounting method
The substantial payout was only possible because AmerisourceBergen relied on a controversial accounting method: excluding legal settlement costs from its year-end CEO evaluation.
Source: washingtonpost.com